Progress in Pseudotyping Lentiviral Vectors Towards Cell-Specific Gene Delivery In Vivo

Area of Science:

• Gene Therapy
• Molecular Biology
• Immunology

Background:

• Lentiviral vectors (LVs) are crucial for gene therapy, enabling stable gene expression in various cell types.
• Current ex vivo gene therapy using LVs, like CAR-T cell production, is costly and complex.
• Direct in vivo gene delivery is explored to reduce costs and bypass ex vivo manipulations.

Purpose of the Study:

• To review advancements in engineering lentiviral vector (LV) tropism for targeted in vivo gene delivery.
• To discuss strategies for achieving cell-type-specific delivery and immune evasion using modified LV envelopes.
• To highlight the potential of in vivo gene therapy for improving treatment accessibility and affordability.

Main Methods:

• Review of literature on lentiviral vector engineering for cell tropism.
• Analysis of heterologous viral envelopes and surface protein modifications.
• Examination of strategies for in vivo gene delivery and immune evasion.

Main Results:

• Modifying LV surface proteins allows for engineered cell tropism.
• Successful in vivo generation of CAR T cells demonstrates the potential of this approach.
• Targeted in vivo delivery can potentially overcome limitations of ex vivo gene therapy.

Conclusions:

• Engineering LV tropism is key for effective in vivo gene therapy.
• In vivo approaches using modified LVs can enhance treatment affordability and accessibility.
• Further research in LV tropism engineering holds promise for future gene therapies.